Trodelvy (sacituzumab govitecan-hziy) is a Trop-2-directed antibody-drug conjugate. It delivers SN-38, a topoisomerase-1 inhibitor, to Trop-2-expressing tumor cells, blocking DNA replication and causing cell death.
Sacituzumab Govitecan
Generic Name/API:Sacituzumab govitecan
Packaging:180 mg in 1 vial per pack
Storage:Store vials in a refrigerator at 2°C to 8°C (36°F to 46°F)
Dosage:For injection: 180 mg off-white to yellowish lyophilized powder in a single-dose vial.
Strength:180 mg
Indication:Trodelvy® (sacituzumab govitecan-hziy) is a Trop-2-directed antibody-drug conjugate used to treat metastatic triple-negative and HR+/HER2- breast cancers in adults who have received prior therapies. It delivers SN-38, a topoisomerase-1 inhibitor, to Trop-2-expressing tumor cells, blocking DNA replication and causing cell death.
Trodelvy® (sacituzumab govitecan-hziy) is a Trop-2-directed antibody-drug conjugate that delivers SN-38, a topoisomerase-1 inhibitor, to Trop-2-expressing cancer cells. It treats adults with metastatic triple-negative breast cancer (TNBC) after two or more prior therapies, and HR+/HER2- metastatic breast cancer after endocrine and systemic therapies. It’s also used for locally advanced or metastatic urothelial cancer post-platinum and PD-1/PD-L1 inhibitor treatment.
STRENGTH
For injection: 180 mg off-white to yellowish lyophilized powder in a single-dose vial.
DOSAGE
- The recommended dosage is 10 mg/kg administered, only as an intravenous infusion, once weekly on days 1 and 8 of 21 day treatment cycles.
- Continue treatment until disease progression or unacceptable toxicity.
- No dose higher than 10 mg/kg is recommended.
- First infusion is administered over 3 hours. Continuous monitoring during and 30 minutes post infusion for infusion-related reactions is advised.
- For subsequent infusions, administration over 1 to 2 hours, given no reactions to previous infusions, and observation during and 30 mins post infusion.
SIDE EFFECTS
Following are the side effects of trodelvy treatment:
- Neutropenia
- Diarrhea
- Hypersensitivity and Infusion-Related Reactions
- Nausea and Vomiting
STORAGE
- Store vials in a refrigerator at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light until time of reconstitution.
- Do not freeze.
-
Neutropenia (reported in 61% patients undergoing trodelvy infusion)
Neutropenia of severe, life threatening or fatal grade observed in patients treated with trodelvy. Treatment must be withheld for neutropenic fever and for neutropenia, wait till neutrophil count drops below 1500 per mm3 on Day 1 of any cycle or below 1000 per mm3 on Day 8 of any cycle.
-
Diarrhea (reported in 65% patients receiving treatment )
This treatment may cause severe diarrhoea. Withhold treatment in case of Grade 3 or 4 and resume on resolution till Grade 1 or below level of symptoms.. Excessive cholinergic response, in addition to diarrhea, consisting of abdominal cramping, salivation may be given medication like atropine for further treatments.
-
Hypersensitivity and infusion-related reactions
Serious anaphylactic reactions, including those potentially life threatening, along with cardiac arrest, hypotension, wheezing, angioedema, swelling, pneumonitis and dermatological reactions. Hypersensitivity reactions can be avoided with premedication, and prepared emergency equipment.
-
Nausea and vomiting (66% and 39% respectively)
Due to emetogenic properties, premedicate patients with 2 or 3 drug combinations regimen like dexamethasone+5-HT3 receptor antagonist/NK1 receptor antagonist. Withhold treatment and resume on resolution of symptoms, with additional measures like antiemetics and take home medications.
-
Increased risk of adverse reactions in patients with reduced UGT1A1 activity
Patients who exhibit homozygosity for uridine diphosphate-glucuronosyltransferase 1A1 *28 allele have an increased chance of neutropenia, febrile neutropenia and anemia, as well as other adverse reactions. Such patients are to be closely monitored and treatment may be withheld or permanently stopped based on clinical assessment of the patient’s manifestations.
-
Embryo fetal toxicity
Sacitizumab govitecan-hiiy can cause teratogenicity and /or embryo fetal lethality, genotoxicity in pregnant women undergoing treatment due to components like SN-38.
FAQ
What is cost of Trodelvy in India?
Trodelvy price may vary each time, as the medicine is not approved in India and must be imported. Factors such as international currency exchange rates (USD/EUR) and import duties can affect the final cost. For more details, please contact 247 QualityMeds.
What is Trodelvy used for?
It is used to treat metastatic triple-negative and HR+/HER2- breast cancers in adults who have received prior therapies.
What are the common side effects of Trodelvy use?
Neutropenia, diarrhea, hypersensitivity and infusion-related reactions, nausea and vomiting are the common side effects.
Can Trodelvy be used in specific populations i.e. for pregnant, breastfeeding, pediatric and geriatric use?
Trodelvy may have teratogenic effects and can cause embryo-fetal lethality when administered during pregnancy. The risk of major birth defects and miscarriage associated with Trodelvy is not fully known; therefore, women should be informed of the potential risks to the fetus.
There is no available data on the presence of sacituzumab govitecan-hziy or its active metabolite SN-38 in human milk, its effect on milk production, or its impact on breastfed infants. As a precaution, women are advised to avoid breastfeeding during treatment and for at least one month after the final dose.
Due to the potential for genotoxicity, both men and women should use effective contraception during treatment.
No dosage adjustment is necessary for patients with mild hepatic impairment. However, the safety of Trodelvy in individuals with moderate to severe hepatic impairment has not been adequately established, despite the association of the drug with liver metastases.
Trodelvy has not been studied in pediatric patients. In geriatric patients aged 65 and older, no significant differences in safety or efficacy were observed compared to younger adults.
How to buy Trodelvy in India?
To buy Trodelvy in India, contact 247 Quality Meds. We assist you in importing this medication legally and at the best possible price.
What are the key criteria for selecting a supplier?
While selecting a supplier, we essentially ensure that the supplier holds a valid Good Distribution Practice (GDP) certificate and possesses a valid operating license. These credentials confirm that the suppliers adherence to International standards for the proper distribution of medicinal product.
How to buy Trodelvy (Sacituzumab Govitecan) online in India?
To buy Trodelvy (sacituzumab govitecan) online in India at a genuine price, reach out to 24/7QualityMeds. We support patients with legal medicine import, verify prescriptions, source from trusted suppliers, and ensure safe doorstep delivery across India.
How to buy Sacituzumab Govitecan (Trodelvy) in Delhi?
To buy Sacituzumab Govitecan (Trodelvy) in Delhi, 24/7QualityMeds supports the complete import process, from prescription verification and import documentation to verified global sourcing and compliant delivery.
